This is a discussion on TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Lung cancer (non-small cell, first line treatment) - pemetrexed . It links to ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
|
|||
|
The summary for the published technology appraisal on Lung cancer (non-small cell, first line treatment) - pemetrexed . It links to the published guidance and key documents.
More... |
![]() |
| Thread Tools | |
| Display Modes | |
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA124: Lung cancer (non-small-cell) - pemetrexed | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 11:51 AM |
| TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 11:51 AM |
| TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed | industry_news | Updates from the Technology Assessment Authorities | 0 | 09-22-2009 07:06 PM |
| TA162: Lung cancer (non-small-cell) - erlotinib | industry_news | Updates from the Technology Assessment Authorities | 0 | 11-25-2008 11:03 PM |
| First-Line Chemo for Small-Cell Lung Cancer is Not Superior to Second-Line | industry_news | Other Clinical Pharmacy News | 0 | 10-08-2008 08:21 AM |